Navigation Links
PharmaNet Development Group, Inc. Expands Latin America Operations with Opening of Brazil Office
Date:2/18/2009

PRINCETON, N.J., Feb. 18 /PRNewswire-FirstCall/ -- PharmaNet Development Group, Inc. (the "Company") (Nasdaq: PDGI), a leading provider of clinical development services to innovative pharmaceutical, biotechnology, generic drug and medical device companies, today announced the opening of a new office in Sao Paulo, Brazil to further enhance its Latin American presence.

PharmaNet has been providing clinical trial support in Latin America since 2002 with a network of field-based staff in Brazil, Mexico and Peru and an office in Argentina which opened in 2003. The new office in Sao Paulo, Brazil underscores the Company's commitment to serve the needs of its clients in this region. Brazil is a highly desired location for clinical research due to its qualified investigators, large patient population, high standard of care and rigorous regulatory standards which are aligned with US and EU regulations.

"The number of clinical trials in Latin America has experienced significant growth over the past ten years," said Fernanda Duran, executive director, Latin American operations. "Our clients are more actively requesting Latin American sites in order to meet aggressive timelines for patient recruitment, thus bringing their new drugs to market sooner. I am thrilled about opening this office in Brazil which will enhance our infrastructure in the region."

"We are excited to continue our expansion into Latin America, a region which offers excellent resources for conducting clinical trials," said Jeffrey P. McMullen, president and chief executive officer. "In addition to our Buenos Aires office, we have superior field-based staff in the area and the new office will provide them with the facilities to continue to demonstrate their high-quality work for our clients."

PharmaNet's increased presence and capacity in th
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. PharmaNet Development Group Agrees to be Acquired by JLL Partners
2. An Affiliate of JLL Partners, Inc. Commences Cash Tender Offer to Acquire PharmaNet Development Group, Inc. at $5.00 per Share
3. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
4. Anesiva to Host Conference Call and Webcast Tomorrow to Discuss Encouraging Development in Zingo(TM) Program
5. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
6. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
7. Global Experts Explore Entire Spectrum of Aids Vaccine Development
8. Vical Names Andrew de Guttadauro Vice President, Corporate Development
9. Operon Biotechnologies and DNA2.0 Announce Co-Marketing and Technology Development Partnership
10. SemBioSys updates Apo AI development program
11. MedImmune Licenses Reverse Genetics Technology to Novartis for Use in Influenza Vaccine Development and Production
Post Your Comments:
*Name:
*Comment:
*Email: